Replies to post #4542 on RespireRx Pharmaceuticals Inc (fka RSPI)

[neuroinv]

One other thought about the import of this deal for Cortex: profile. There will be a lot of analysis over the next several weeks about the pros and cons of this deal, what does SP get for its $14.4 billion? Fred Hassan is always an interesting character to look at, he's more colorful than most of his peers. This means that the Cortex/Organon partnership, and the value of the Ampakines for sz and dep, will also be looked at in a way that it never was when it was a deal with Organon for a few million.

IMHO--this will continue to be helpful to Cortex and its valuation. It already has been.

One of the inevitable conjectures will be--could Hassan and SP be so forward looking and creative that their next step would be to reunite the worldwide rights for the best Ampakine platform in the world for all indications, under one roof? All Hassan has to do is round up $14.4 billion to $15 billion by buying Cortex for $600 million. Instant major pipeline at the cost of just rounding up to the next billion....this is intended to be 70% tongue-in-cheek. The other 30%....

NeuroInvestment

[Market_Fest4]

GFP,
I don't see a reason for today's spike in your price movement scenarios. What do you think is behind this move today? Is it follow-thru from last weeks strong finish? Is it JerryDylan's reverse head and shoulders? Is it speculation that Schering-plough will make a bid for COR in a few months?

I sure am glad I bought some around $2 - feels better than $2.40 But, I suppose $2.40 would feel better than $4. At $2.50, it would be the same price it fell to April 3rd, 2006 just after the FDA announced the hold and we had no idea what was wrong with CX-717.

Eleven months later that question has been answered, CX-717 is still extremely safe, minus any ambiguity, and it would seem the FDA will remove all dosing restrictions shortly. CX-717 appears to be the ideal medication for ADHD, not to mention the other orphan indications. It's hard to imagine that a BP will ignore COR for much longer. There might be pending deals already in the works contingent upon an FDA blessing? COR was trading at $5.25 on March 31, 2006.

Sometimes CD's pale in comparison. I'm sorry you couldn't find a few bucks to get in cheaper, as closely as you've followed COR over the years.
MF4